Olaparib Plus Durvalumab in Recurrent Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: A Proof-of-Concept Phase II Study
Clin. Cancer Res 2020 Jul 01;[EPub Ahead of Print], EJ Lampert, A Zimmer, M Padget, A Cimino-Mathews, JR Nair, Y Liu, EM Swisher, JW Hodge, AB Nixon, E Nichols, MH Bagheri, E Levy, MR Radke, S Lipkowitz, CM Annunziata, JM Taube, SM Steinberg, JM LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.